Literature DB >> 12443892

Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants.

Silvia Bozza1, Roberta Gaziano, Grayson B Lipford, Claudia Montagnoli, Angela Bacci, Paolo Di Francesco, Viswanath P Kurup, Hermann Wagner, Luigina Romani.   

Abstract

In a murine model of invasive pulmonary aspergillosis, dendritic cells (DCs) pulsed with Aspergillus antigens induced the activation of CD4(+) Th1 cells capable of conferring resistance to the infection. Here we show that the combined, local delivery of unmethylated CpG oligodeoxynucleotides (ODNs) and the Asp f 16 Aspergillus allergen resulted in the functional maturation and activation of airway DCs capable of inducing Th1 priming and resistance to the fungus. Therefore, ODNs act as a potent adjuvant for the vaccine-induced protection against the fungus by promoting dominant Th1 response to Aspergillus antigens and allergens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12443892     DOI: 10.1016/s1286-4579(02)00007-2

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  46 in total

1.  Neutropenia enhances lung dendritic cell recruitment in response to Aspergillus via a cytokine-to-chemokine amplification loop.

Authors:  Stacy J Park; Marie D Burdick; William K Brix; Mark H Stoler; David S Askew; Robert M Strieter; Borna Mehrad
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis.

Authors:  James I Ito; Joseph M Lyons; Teresa B Hong; Daniel Tamae; Yi-Kuang Liu; Sharon P Wilczynski; Markus Kalkum
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

Review 3.  Aspergillus vaccines: Hardly worth studying or worthy of hard study?

Authors:  Stuart M Levitz
Journal:  Med Mycol       Date:  2016-09-17       Impact factor: 4.076

4.  Intrapulmonary, adenovirus-mediated overexpression of KARAP/DAP12 enhances fungal clearance during invasive aspergillosis.

Authors:  Kristin J Carpenter; Karen F Buckland; Zhou Xing; Cory M Hogaboam
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 5.  Vaccine immunity against fungal infections.

Authors:  Som G Nanjappa; Bruce S Klein
Journal:  Curr Opin Immunol       Date:  2014-03-03       Impact factor: 7.486

6.  Intranasal CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and -independent manner.

Authors:  Hemanth Ramaprakash; Cory M Hogaboam
Journal:  Int Arch Allergy Immunol       Date:  2009-12-16       Impact factor: 2.749

7.  Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model of allergic aspergillosis.

Authors:  Banani Banerjee; Kevin J Kelly; Jordan N Fink; James D Henderson; Naveen K Bansal; Viswanath P Kurup
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines.

Authors:  Wenjun Xiao; Lanying Du; Chao Liang; Jie Guan; Shibo Jiang; Sara Lustigman; Yuxian He; Yusen Zhou
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

9.  Intratracheal synthetic CpG oligodeoxynucleotide causes acute lung injury with systemic inflammatory response.

Authors:  Sadatomo Tasaka; Hirofumi Kamata; Keisuke Miyamoto; Yasushi Nakano; Hiromi Shinoda; Yoshifumi Kimizuka; Hiroshi Fujiwara; Naoki Hasegawa; Seitaro Fujishima; Taku Miyasho; Akitoshi Ishizaka
Journal:  Respir Res       Date:  2009-09-23

10.  Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus.

Authors:  Mark Schütte; Philippe Thullier; Thibaut Pelat; Xenia Wezler; Philip Rosenstock; Dominik Hinz; Martina Inga Kirsch; Mike Hasenberg; Ronald Frank; Thomas Schirrmann; Matthias Gunzer; Michael Hust; Stefan Dübel
Journal:  PLoS One       Date:  2009-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.